Cyclosporine vs tacrolimus therapy for posterior and itnermediate uveitis

C. C. Murphy, Kathrin Greiner, Jarka Plskova, Linda Duncan, N. A. Frost, John Vincent Forrester

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

Objectives: To compare the efficacy and tolerability of tacrolimus and cyclosporine therapy for noninfectious posterior segment intrancular inflammation and to evaluate their effect on peripheral blood CD4(+) T-cell phenotype and activation status.

Methods: Thirty-seven patients who required second-line immunosuppression for posterior segment intraocular inflammation were enrolled in this prospective randomized trial of tacrolimus vs cyclosporine therapy. The main outcome measures were visual acuity, binocular indirect ophthalmoscopy score, adverse effects, and quality of life. In addition, peripheral blood CD4(+) T-cell phenotype and activation status were evaluated by now cytometry before treatment and at 2, 4, and 12 weeks using CD69, chemokine receptor (CCR4, CCR5, and CXCR3), and intracellular cytokine (tumor necrosis factor α, interferon-γ, and interleukin 10) expression.

Results: Thirteen patients (68%) taking tacrolimus and 12 patients (67%) taking cyclosporine responded to treatment. Cyclosporine therapy was associated with a higher incidence of reported adverse effects. Mean arterial pressure and serum cholesterol level were significantly higher at 3 months in the cyclosporine group than the tacrolimus group. No significant difference was detected with regard to effect on quality of life or CD4(+) T-cell phenotype.

Conclusions: Tacrolimus and cyclosporine were similar with regard to efficacy for posterior segment intraocular inflammation, but the results suggested a more favorable safety profile for tacrolimus therapy.

Original languageEnglish
Pages (from-to)634-641
Number of pages7
JournalArchives of Ophthalmology
Volume123
DOIs
Publication statusPublished - 2005

Keywords

  • LOW-DOSE CYCLOSPORINE
  • RENAL-TRANSPLANT PATIENTS
  • CD4(+) T-CELLS
  • A THERAPY
  • FK506
  • TRIAL
  • MULTICENTER
  • DISEASE
  • HYPERLIPIDEMIA
  • HYPERTENSION

Cite this

Murphy, C. C., Greiner, K., Plskova, J., Duncan, L., Frost, N. A., & Forrester, J. V. (2005). Cyclosporine vs tacrolimus therapy for posterior and itnermediate uveitis. Archives of Ophthalmology, 123, 634-641. https://doi.org/10.1001/archopht.123.5.634

Cyclosporine vs tacrolimus therapy for posterior and itnermediate uveitis. / Murphy, C. C.; Greiner, Kathrin; Plskova, Jarka; Duncan, Linda; Frost, N. A.; Forrester, John Vincent.

In: Archives of Ophthalmology, Vol. 123, 2005, p. 634-641.

Research output: Contribution to journalArticle

Murphy, CC, Greiner, K, Plskova, J, Duncan, L, Frost, NA & Forrester, JV 2005, 'Cyclosporine vs tacrolimus therapy for posterior and itnermediate uveitis', Archives of Ophthalmology, vol. 123, pp. 634-641. https://doi.org/10.1001/archopht.123.5.634
Murphy, C. C. ; Greiner, Kathrin ; Plskova, Jarka ; Duncan, Linda ; Frost, N. A. ; Forrester, John Vincent. / Cyclosporine vs tacrolimus therapy for posterior and itnermediate uveitis. In: Archives of Ophthalmology. 2005 ; Vol. 123. pp. 634-641.
@article{e1d6069d60934f389dd0dd2840a436d0,
title = "Cyclosporine vs tacrolimus therapy for posterior and itnermediate uveitis",
abstract = "Objectives: To compare the efficacy and tolerability of tacrolimus and cyclosporine therapy for noninfectious posterior segment intrancular inflammation and to evaluate their effect on peripheral blood CD4(+) T-cell phenotype and activation status.Methods: Thirty-seven patients who required second-line immunosuppression for posterior segment intraocular inflammation were enrolled in this prospective randomized trial of tacrolimus vs cyclosporine therapy. The main outcome measures were visual acuity, binocular indirect ophthalmoscopy score, adverse effects, and quality of life. In addition, peripheral blood CD4(+) T-cell phenotype and activation status were evaluated by now cytometry before treatment and at 2, 4, and 12 weeks using CD69, chemokine receptor (CCR4, CCR5, and CXCR3), and intracellular cytokine (tumor necrosis factor α, interferon-γ, and interleukin 10) expression.Results: Thirteen patients (68{\%}) taking tacrolimus and 12 patients (67{\%}) taking cyclosporine responded to treatment. Cyclosporine therapy was associated with a higher incidence of reported adverse effects. Mean arterial pressure and serum cholesterol level were significantly higher at 3 months in the cyclosporine group than the tacrolimus group. No significant difference was detected with regard to effect on quality of life or CD4(+) T-cell phenotype.Conclusions: Tacrolimus and cyclosporine were similar with regard to efficacy for posterior segment intraocular inflammation, but the results suggested a more favorable safety profile for tacrolimus therapy.",
keywords = "LOW-DOSE CYCLOSPORINE, RENAL-TRANSPLANT PATIENTS, CD4(+) T-CELLS, A THERAPY, FK506, TRIAL, MULTICENTER, DISEASE, HYPERLIPIDEMIA, HYPERTENSION",
author = "Murphy, {C. C.} and Kathrin Greiner and Jarka Plskova and Linda Duncan and Frost, {N. A.} and Forrester, {John Vincent}",
year = "2005",
doi = "10.1001/archopht.123.5.634",
language = "English",
volume = "123",
pages = "634--641",
journal = "Archives of Ophthalmology",
issn = "0003-9950",
publisher = "American Medical Association",

}

TY - JOUR

T1 - Cyclosporine vs tacrolimus therapy for posterior and itnermediate uveitis

AU - Murphy, C. C.

AU - Greiner, Kathrin

AU - Plskova, Jarka

AU - Duncan, Linda

AU - Frost, N. A.

AU - Forrester, John Vincent

PY - 2005

Y1 - 2005

N2 - Objectives: To compare the efficacy and tolerability of tacrolimus and cyclosporine therapy for noninfectious posterior segment intrancular inflammation and to evaluate their effect on peripheral blood CD4(+) T-cell phenotype and activation status.Methods: Thirty-seven patients who required second-line immunosuppression for posterior segment intraocular inflammation were enrolled in this prospective randomized trial of tacrolimus vs cyclosporine therapy. The main outcome measures were visual acuity, binocular indirect ophthalmoscopy score, adverse effects, and quality of life. In addition, peripheral blood CD4(+) T-cell phenotype and activation status were evaluated by now cytometry before treatment and at 2, 4, and 12 weeks using CD69, chemokine receptor (CCR4, CCR5, and CXCR3), and intracellular cytokine (tumor necrosis factor α, interferon-γ, and interleukin 10) expression.Results: Thirteen patients (68%) taking tacrolimus and 12 patients (67%) taking cyclosporine responded to treatment. Cyclosporine therapy was associated with a higher incidence of reported adverse effects. Mean arterial pressure and serum cholesterol level were significantly higher at 3 months in the cyclosporine group than the tacrolimus group. No significant difference was detected with regard to effect on quality of life or CD4(+) T-cell phenotype.Conclusions: Tacrolimus and cyclosporine were similar with regard to efficacy for posterior segment intraocular inflammation, but the results suggested a more favorable safety profile for tacrolimus therapy.

AB - Objectives: To compare the efficacy and tolerability of tacrolimus and cyclosporine therapy for noninfectious posterior segment intrancular inflammation and to evaluate their effect on peripheral blood CD4(+) T-cell phenotype and activation status.Methods: Thirty-seven patients who required second-line immunosuppression for posterior segment intraocular inflammation were enrolled in this prospective randomized trial of tacrolimus vs cyclosporine therapy. The main outcome measures were visual acuity, binocular indirect ophthalmoscopy score, adverse effects, and quality of life. In addition, peripheral blood CD4(+) T-cell phenotype and activation status were evaluated by now cytometry before treatment and at 2, 4, and 12 weeks using CD69, chemokine receptor (CCR4, CCR5, and CXCR3), and intracellular cytokine (tumor necrosis factor α, interferon-γ, and interleukin 10) expression.Results: Thirteen patients (68%) taking tacrolimus and 12 patients (67%) taking cyclosporine responded to treatment. Cyclosporine therapy was associated with a higher incidence of reported adverse effects. Mean arterial pressure and serum cholesterol level were significantly higher at 3 months in the cyclosporine group than the tacrolimus group. No significant difference was detected with regard to effect on quality of life or CD4(+) T-cell phenotype.Conclusions: Tacrolimus and cyclosporine were similar with regard to efficacy for posterior segment intraocular inflammation, but the results suggested a more favorable safety profile for tacrolimus therapy.

KW - LOW-DOSE CYCLOSPORINE

KW - RENAL-TRANSPLANT PATIENTS

KW - CD4(+) T-CELLS

KW - A THERAPY

KW - FK506

KW - TRIAL

KW - MULTICENTER

KW - DISEASE

KW - HYPERLIPIDEMIA

KW - HYPERTENSION

U2 - 10.1001/archopht.123.5.634

DO - 10.1001/archopht.123.5.634

M3 - Article

VL - 123

SP - 634

EP - 641

JO - Archives of Ophthalmology

JF - Archives of Ophthalmology

SN - 0003-9950

ER -